PATENT CLAIM ANALYSIS

Application Number: 16067229
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-01
Patent Classification: ["514", "248000"]

Abstract:
The present invention relates to a crystalline form of a BTK kinase inhibitor and the preparation method thereof. In particular, the present invention relates to a crystal form I of (R)-4-amino-1-(1-(but-2-ynoyl)pyrrolidin-3-yl)-3-(4-(2,6-difluorophenoxy)phenyl)-1H-pyrrolo[2,3-d]pyridazin-7(6H)-one (the compound of formula (I)) and the preparation method thereof. The crystal form I of the compound of formula (I) obtained by the present invention has a good crystalline stability and chemical stability, and the crystallization solvent used has a low toxicity and low residue, thus making it more suitable for use in clinical treatment.

Claim (Index 3):
The crystal form I according to  claim 1 , wherein the X-ray powder diffraction spectrum comprises peaks at diffraction angles 2\u03b8\u00b10.2 of about 5.11, 7.86, 9.91, 12.20, 13.73, 15.44, 17.24, 17.64, 19.02, 19.93, 20.72, 21.48, 22.64, 23.12, 24.81, 25.43, 26.24, 27.44, 27.87, and 29.03.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 94.0
- Lexical Diversity: 1.92308
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15546405', '15952234', '15516529', '15559516', '14418484']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7834515108825665
- 35 USC 102 Novelty (BERT): 0.4946817988317766
- Combined Prediction Score: 0.7545745396774874
- Mean Citation Score: 242.225378
- Max Citation Score: 250.81743
- Similarity Product: 201.6053127465427

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test